Autologous anti-HER2-CAR-4-1BB-CD3zeta-CD19t+-expressing Tcm-enriched T lymphocytes

{
  "id": "MLC-T-ONC-011454",
  "term": "Autologous anti-HER2-CAR-4-1BB-CD3zeta-CD19t+-expressing Tcm-enriched T lymphocytes",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of genetically modified autologous central memory (Tcm) enriched T cells transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-human epidermal growth factor 2 (HER2) single chain variable fragment (scFv) derived from trastuzumab, with a 4-1BB (CD137) costimulatory domain that is linked to the signaling domain of the T-cell antigen receptor complex zeta chain (CD3-zeta) (BBz), and truncated CD19 (CD19t), with potential immunostimulatory and antineoplastic activities. Upon intravenous infusion, Anti-HER2-CAR-4-1BB-CD19t+-expressing Tcm-enriched T lymphocytes are directed against HER2-expressing cells, thereby inducing selective toxicity in HER2-expressing tumor cells. HER2, a receptor tyrosine kinase, is mutated or overexpressed in many tumor cell types, plays a significant role in tumor cell proliferation and tumor vascularization. The BBz costimulatory signaling domain enhances proliferation of T cells and antitumor activity, while CD19t, a marker for transduction, is utilized to calculate CAR-T-cell dosing and for CAR-expressing cell tracking. Tcm cells have the capacity for long-lived persistence and retain their ability to proliferate upon antigen re-encounter. The immunoglobulin G4 (IgG4) extracellular spacer contains a double mutation, (L235E;N297Q) (EQ) within the CH2 region to reduce Fc receptor recognition.",
  "synonyms": [
    "autologous HER2(EQ)BBζ/CD19t+ Tcm cells",
    "autologous memory enriched HER2(EQ)BBzeta/CD19t+-expressing T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-anti-her2-car-4-1bb-cd3zeta-cd19t-plus-expressing-tcm-enriched-t/"
}